Neurology
- Active ingredient (INN)
- haloperidol
- Composition (active ingredients)
- haloperidol - 5,0 mg
- Фармакотерапевтическая группа
- antipsychotic
- Pharmacotherapeutic group
- solution for intravenous and intramuscular administration of 5 mg/ml 1 ml, 2 ml; №5, №100
- Сonditions of supply
- on prescription
Indications
Relief and treatment of acute psychotic disorders accompanied by psychomotor agitation.Behavioral disorders, such as aggression, hyperactivity, a tendency to self-harm, in the mentally retarded and in patients with organic brain lesions.
Treatment of nausea and vomiting.
Dosage regimen
Intramuscularly, intravenously.
The dose of the drug for all indications is set individually under the supervision of a physician. To determine the starting dose, patient age, severity of symptoms, and previous response to antipsychotics should be considered.
Elderly patients, weakened and with previously identified adverse reactions to antipsychotics, may require a lower dose of haloperidol, the initial dose for such patients should be half the usual dose for adults, and then gradually corrected to achieve an optimal response to therapy.
In case of liver failure, the dose must be reduced.
Haloperidol should be prescribed in the lowest clinically effective dose.
Parenteral administration should be as short as possible followed by a transition to oral administration.
- Schizophrenia, psychosis, mania, hypomania, mental or behavioral disorders, psychomotor agitation, excitement, violent or dangerous impulsive behavior, organic brain damage
-
5 mg is administered until symptom control is achieved every hour or up to a maximum dose of 20 mg/day
- For the treatment of nausea and vomiting
-
1-2 mg
